Dipeptidyl Peptidase-4 Inhibition on Glucagon-like Peptide-1 (GLP-1)
Launched by JOHNS HOPKINS UNIVERSITY · Jul 24, 2009
Trial Information
Current as of June 02, 2025
Terminated
Keywords
ClinConnect Summary
The purpose of the present proposal is to 1) examine the role of dipeptidyl peptidase (DPP-4) inhibition on insulin release during a hyperglycemic clamp while GLP-1 is being infused and, 2) further elucidate the role of the metabolite of GLP-1, that is GLP-1 9-36 amide (GLP-1m). During stable and very reproducible elevated plasma glucose levels the effect of increased active incretin levels with DPP-4 inhibitors should result in increased plasma insulin levels. Therefore the aim of this protocol is to document whether plasma insulin levels are increased following GLP-1 infusion in the prese...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Hct level of at least 34% for women and 36% for men
- • Women of non-bearing potential and women of childbearing potential using adequate contraception
- • Serum creatine level of less than 1.7 mg/dl
- * Four groups:
- • Age 21-45 (BMI between 18.50-24.99) \& (BMI between 30-35)
- • Age greater than 65 years (BMI between 18.50-24.99) \& (BMI between 30-35)
- Exclusion Criteria:
- • Pregnant and/or lactating females
- • Women of childbearing potential not willing to use adequate contraception
- • Hct below inclusion criteria
- • Serum creatine level greater than 1.8 mg/dl
- • Age less than 21 and age between 46-64
- • Diabetes mellitus
- • BMI less than 18 and BMI greater than 35
About Johns Hopkins University
Johns Hopkins University, a prestigious research institution located in Baltimore, Maryland, is renowned for its commitment to advancing medical science and public health through innovative clinical trials. With a rich history of groundbreaking research and a multidisciplinary approach, the university's clinical trial initiatives focus on translating scientific discoveries into effective treatments and interventions. Leveraging state-of-the-art facilities and a collaborative network of experts, Johns Hopkins University conducts rigorous clinical studies that aim to improve patient outcomes and address critical health challenges. Its dedication to ethical standards and participant safety underscores its role as a leader in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baltimore, Maryland, United States
Patients applied
Trial Officials
Dariush Elahi, PhD
Principal Investigator
Johns Hopkins University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials